Loading...

LivaNova

DB:LIA
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LIA
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • LivaNova has significant price volatility in the past 3 months.
LIA Share Price and Events
7 Day Returns
-4.8%
DB:LIA
-1.3%
DE Medical Equipment
1.8%
DE Market
1 Year Returns
-16.9%
DB:LIA
17.1%
DE Medical Equipment
-6%
DE Market
LIA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
LivaNova (LIA) -4.8% -29.3% -27.2% -16.9% 22.3% -
DE Medical Equipment -1.3% -0.9% 9.7% 17.1% 86% 197.4%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • LIA underperformed the Medical Equipment industry which returned 17.1% over the past year.
  • LIA underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
LIA
Industry
5yr Volatility vs Market

Value

 Is LivaNova undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of LivaNova to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for LivaNova.

DB:LIA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:LIA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.928 (1 + (1- 19%) (5.23%))
0.978
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.98
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.978 * 6.65%)
6.73%

Discounted Cash Flow Calculation for DB:LIA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for LivaNova is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:LIA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.73%)
2019 116.55 Analyst x2 109.20
2020 168.40 Analyst x3 147.82
2021 202.85 Analyst x2 166.83
2022 230.00 Analyst x2 177.23
2023 270.90 Analyst x2 195.58
2024 300.21 Est @ 10.82% 203.07
2025 323.15 Est @ 7.64% 204.80
2026 340.66 Est @ 5.42% 202.27
2027 353.81 Est @ 3.86% 196.83
2028 363.62 Est @ 2.77% 189.53
Present value of next 10 years cash flows $1,793.17
DB:LIA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $363.62 × (1 + 0.23%) ÷ (6.73% – 0.23%)
$5,602.84
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,602.84 ÷ (1 + 6.73%)10
$2,920.36
DB:LIA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,793.17 + $2,920.36
$4,713.52
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,713.52 / 48.28
$97.62
DB:LIA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:LIA represents 0.88073x of NasdaqGS:LIVN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88073x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 97.62 x 0.88073
€85.98
Value per share (EUR) From above. €85.98
Current discount Discount to share price of €59.00
= -1 x (€59.00 - €85.98) / €85.98
31.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price LivaNova is available for.
Intrinsic value
31%
Share price is €59 vs Future cash flow value of €85.98
Current Discount Checks
For LivaNova to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • LivaNova's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • LivaNova's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for LivaNova's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are LivaNova's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LIA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.68
NasdaqGS:LIVN Share Price ** NasdaqGS (2019-04-18) in USD $66.99
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 31.89x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of LivaNova.

DB:LIA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:LIVN Share Price ÷ EPS (both in USD)

= 66.99 ÷ -3.68

-18.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LivaNova is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • LivaNova is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does LivaNova's expected growth come at a high price?
Raw Data
DB:LIA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -18.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
50.6%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.63x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for LivaNova, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on LivaNova's assets?
Raw Data
DB:LIA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $31.19
NasdaqGS:LIVN Share Price * NasdaqGS (2019-04-18) in USD $66.99
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.13x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:LIA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:LIVN Share Price ÷ Book Value per Share (both in USD)

= 66.99 ÷ 31.19

2.15x

* Primary Listing of LivaNova.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LivaNova is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess LivaNova's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. LivaNova has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is LivaNova expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is LivaNova expected to grow at an attractive rate?
  • LivaNova's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • LivaNova's earnings growth is expected to exceed the Germany market average.
  • LivaNova's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LIA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LIA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 50.6%
DB:LIA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 5.1%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LIA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LIA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,423 328 227 1
2022-12-31 1,380 293 194 3
2021-12-31 1,267 256 147 7
2020-12-31 1,204 66 115 9
2019-12-31 1,132 76 89 9
DB:LIA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1,107 120 -178
2018-09-30 1,088 117 0
2018-06-30 1,068 108 33
2018-03-31 1,036 79 59
2017-12-31 1,012 91 54
2017-09-30 795 114 121
2017-06-30 840 109 92
2017-03-31 905 114 55
2016-12-31 965 90 2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • LivaNova's earnings are expected to grow significantly at over 20% yearly.
  • LivaNova's revenue is expected to grow by 5.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LIA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from LivaNova Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LIA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.67 4.67 4.67 1.00
2022-12-31 3.99 3.99 3.99 1.00
2021-12-31 3.03 3.30 2.61 4.00
2020-12-31 2.49 2.85 2.08 5.00
2019-12-31 2.08 2.54 1.76 4.00
DB:LIA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.68
2018-09-30 -0.01
2018-06-30 0.68
2018-03-31 1.22
2017-12-31 1.13
2017-09-30 2.51
2017-06-30 1.90
2017-03-31 1.14
2016-12-31 0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • LivaNova is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess LivaNova's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
LivaNova has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has LivaNova performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare LivaNova's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • LivaNova does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare LivaNova's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare LivaNova's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
LivaNova's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from LivaNova Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LIA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,106.96 -178.46 462.17 146.02
2018-09-30 1,088.33 -0.38 441.89 137.42
2018-06-30 1,067.51 32.91 424.36 121.41
2018-03-31 1,035.85 59.06 397.18 115.23
2017-12-31 1,012.28 54.47 380.10 103.72
2017-09-30 795.50 120.79 292.37 65.51
2017-06-30 839.51 92.20 302.70 68.99
2017-03-31 904.71 55.48 328.58 71.16
2016-12-31 964.86 1.87 355.16 82.08
2015-12-31 544.86 -22.08 220.54 62.87
2015-10-18 294.67 14.38 135.91 44.34
2015-07-24 300.56 56.75 124.30 40.68
2015-04-24 291.56 57.85 123.62 42.25
2015-01-23 292.34 65.76 126.20 43.55
2014-10-24 288.46 63.12 124.30 44.31
2014-07-25 285.15 59.74 124.36 45.15
2014-04-25 282.01 54.89 120.64 45.22
2014-01-24 275.51 47.99 118.34 46.38
2013-10-25 270.02 47.28 115.56 45.42
2013-07-26 262.87 46.96 113.50 43.81
2013-04-26 254.32 46.36 112.52 41.55
2013-01-25 243.59 45.49 108.58 38.57
2012-10-26 235.42 41.81 106.87 37.43
2012-07-27 226.16 37.27 104.88 36.27
2012-04-27 218.50 36.08 102.57 34.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if LivaNova has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if LivaNova has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if LivaNova improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess LivaNova's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
LivaNova has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is LivaNova's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up LivaNova's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • LivaNova is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • LivaNova's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of LivaNova's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from LivaNova Company Filings, last reported 3 months ago.

DB:LIA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1,503.74 169.20 47.20
2018-09-30 1,784.99 157.58 79.95
2018-06-30 1,783.03 162.22 47.38
2018-03-31 1,818.98 184.82 64.96
2017-12-31 1,815.31 147.58 93.62
2017-09-30 1,914.43 125.73 65.16
2017-06-30 1,843.52 127.42 42.69
2017-03-31 1,734.93 123.58 62.72
2016-12-31 1,706.91 125.20 39.79
2015-12-31 1,811.46 177.20 119.61
2015-10-18 278.39 0.00 196.78
2015-07-24 293.18 0.00 169.35
2015-04-24 276.57 0.00 151.21
2015-01-23 271.12 0.00 143.22
2014-10-24 269.89 0.00 141.91
2014-07-25 264.32 0.00 132.73
2014-04-25 259.10 0.00 128.33
2014-01-24 240.25 0.00 116.60
2013-10-25 236.00 0.00 122.73
2013-07-26 234.64 0.00 131.31
2013-04-26 229.57 0.00 135.71
2013-01-25 224.39 0.00 131.53
2012-10-26 204.82 0.00 118.50
2012-07-27 188.82 0.00 102.29
2012-04-27 183.47 0.00 96.65
  • LivaNova's level of debt (11.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 11.3% today).
  • Debt is well covered by operating cash flow (71.2%, greater than 20% of total debt).
  • LivaNova is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess LivaNova's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. LivaNova has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is LivaNova's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from LivaNova dividends. Estimated to be 0% next year.
If you bought €2,000 of LivaNova shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate LivaNova's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate LivaNova's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LIA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LIA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as LivaNova has not reported any payouts.
  • Unable to verify if LivaNova's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of LivaNova's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as LivaNova has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of LivaNova's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess LivaNova's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can LivaNova afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. LivaNova has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of LivaNova's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Damien McDonald
COMPENSATION $5,415,761
AGE 53
TENURE AS CEO 2.3 years
CEO Bio

Mr. Damien McDonald is the Chief Executive Officer and an Executive Director of LivaNova PLC. since January 1, 2017. Mr. McDonald served as Chief Operating Officer of LivaNova from October 3, 2016 through December 31, 2016. Prior to joining us, Mr. McDonald held several senior roles in the global life sciences sector. Most recently, Mr. McDonald was Group Executive and Corporate Vice President at Danaher Corporation (“Danaher”). From 2013 until 2016, he served as Group President, Professional Consumables at Danaher. During his tenure at Danaher, he was responsible for, among other things, 13 operating plants in Europe and the Americas and over 3,200 employees globally. From 2011 to 2013, Mr. McDonald served as Group President of Kerr Corporation, a subsidiary of Danaher, where he was responsible for a dental consumables business with operations in the United States, Mexico, Switzerland, Italy and the Czech Republic. In 2010, Mr. McDonald undertook special projects for Danaher. From 2007 to 2010, Mr. McDonald was President, Zimmer Spine at Zimmer Holdings, where he was responsible for divisions in the United States and France. From 1999 to 2007, Mr. McDonald occupied various roles with Johnson and Johnson. He has been a Non-Executive Director of Avita Medical Limited since January 13, 2016. Mr. McDonald holds bachelor’s degrees in pharmacy and economics from the University of Queensland in Australia, a master’s degree in international economics from the University of Wales, and an MBA from the Institute for Management Development in Lausanne.

CEO Compensation
  • Damien's compensation has been consistent with company performance over the past year.
  • Damien's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the LivaNova management team in years:

1.9
Average Tenure
54
Average Age
  • The average tenure for the LivaNova management team is less than 2 years, this suggests a new team.
Management Team

Damien McDonald

TITLE
CEO & Director
COMPENSATION
$5M
AGE
53
TENURE
2.3 yrs

Thad Huston

TITLE
Chief Financial Officer
COMPENSATION
$4M
AGE
48
TENURE
1.9 yrs

Douglas Manko

TITLE
Chief Accounting Officer
COMPENSATION
$801K
AGE
44
TENURE
2.8 yrs

Keyna Skeffington

TITLE
General Counsel & Senior VP
COMPENSATION
$976K
AGE
55
TENURE
1.8 yrs

David Wise

TITLE
Senior Advisor
COMPENSATION
$1M
AGE
63
TENURE
0.1 yrs

Melissa Farina

TITLE
Vice President of Investor Relations

Deanna Wilke

TITLE
Director of Corporate Communications

Matt Dodds

TITLE
Senior Vice President of Corporate Development
TENURE
1.3 yrs

Trui Hebbelinck

TITLE
Chief Human Resources Officer
TENURE
0.1 yrs

Ed Andrle

TITLE
General Manager of Neuromodulation
AGE
61
TENURE
3.5 yrs
Board of Directors Tenure

Average tenure and age of the LivaNova board of directors in years:

3.5
Average Tenure
62
Average Age
  • The tenure for the LivaNova board of directors is about average.
Board of Directors

Dan Moore

TITLE
Chairman
COMPENSATION
$384K
AGE
57
TENURE
3.6 yrs

Damien McDonald

TITLE
CEO & Director
COMPENSATION
$5M
AGE
53
TENURE
2.3 yrs

Art Rosenthal

TITLE
Independent Director
COMPENSATION
$243K
AGE
71
TENURE
12.3 yrs

Hugh Morrison

TITLE
Independent Director
COMPENSATION
$259K
AGE
71
TENURE
12.4 yrs

Sharon O'Kane

TITLE
Independent Director
COMPENSATION
$238K
AGE
50
TENURE
3.5 yrs

Al Novak

TITLE
Independent Director
COMPENSATION
$246K
AGE
70
TENURE
12.3 yrs

Francesco Bianchi

TITLE
Independent Director
COMPENSATION
$246K
AGE
62
TENURE
3.5 yrs

Andrea Saia

TITLE
Non-Executive Director
COMPENSATION
$238K
AGE
60
TENURE
2.8 yrs

Bill Kozy

TITLE
Director
AGE
66
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
13. Dec 18 Sell Alfred Novak Individual 11. Dec 18 11. Dec 18 -500 €85.80 €-42,901
06. Nov 18 Sell Hugh Morrison Individual 05. Nov 18 05. Nov 18 -1,000 €101.43 €-101,425
17. Aug 18 Sell Douglas Manko Individual 15. Aug 18 15. Aug 18 -440 €107.42 €-47,265
18. Jun 18 Sell Alfred Novak Individual 14. Jun 18 14. Jun 18 -1,000 €89.65 €-89,654
12. Jun 18 Sell Hugh Morrison Individual 08. Jun 18 08. Jun 18 -1,000 €82.49 €-82,490
25. May 18 Sell Francesco Bianchi Individual 23. May 18 23. May 18 -1,830 €71.62 €-131,061
11. May 18 Sell Alfred Novak Individual 09. May 18 09. May 18 -1,000 €70.85 €-70,851
X
Management checks
We assess LivaNova's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. LivaNova has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Details
Name: LivaNova PLC
LIA
Exchange: DB
Founded: 1987
$2,876,097,572
48,282,993
Website: http://www.livanova.com
Address: LivaNova PLC
20 Eastbourne Terrace,
Paddington,
London,
Greater London, W2 6LG,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS LIVN Common Stock Nasdaq Global Select US USD 19. Oct 2015
DB LIA Common Stock Deutsche Boerse AG DE EUR 19. Oct 2015
Number of employees
Current staff
Staff numbers
4,000
LivaNova employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:55
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.